Developer docs
API playgroundTry for free, no card

Search company profiles

HoneyNaps

Full company profile

uuid0000k88

Namestring
HoneyNaps
Legal namestring
HoneyNaps Co., Ltd.
Websiteurl
honeynaps.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

HoneyNaps Co., Ltd. is a South Korea-based sleep health technology company founded in 2015 that develops AI-powered software and biosignal monitoring systems for sleep disorder diagnosis, patient management, and digital therapeutics. Its core platform, SOMNUM, is an FDA 510(k)-cleared deep learning algorithm with an eXplainable Medical AI (XAI) framework that performs real-time automated analysis of multi-channel polysomnography (PSG) biosignals — EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, and snoring — reducing expert scoring time from 3–4 hours to approximately 5 minutes per study. The portfolio is organized around the SOMNUM brand and includes SOMNUM Pro (clinical-grade AI sleep diagnostics), SOMNUM Cloud (cloud-delivered EDF file analysis launched August 2025), SOMNUM Scanning (FCC-certified non-contact radar-based home sleep monitoring), SOMNUM PAX (integrated central monitoring system), and SOMNUM Medella (a digital therapeutic for insomnia built on digital CBT-I), supported by the broader HoneyCube bio-signal management platform.

The company generates revenue through five complementary streams: enterprise AI software licensing to hospitals and sleep centers on a recurring basis, hardware sales of SOMNUM Scanning sensors, professional services for AI-based re-scoring of PSG data in pharmaceutical and medical device clinical trials, technology licensing to over 60 tier-1 medical device companies globally, and consumer-facing hospitality and corporate wellness packages (e.g., partnerships with InterContinental, Novotel, and GS Group). Go-to-market is hybrid: direct enterprise field sales through its Seoul headquarters and Boston/Cambridge U.S. subsidiary (HoneyNaps USA Inc.), a developing international distributor network, event-driven lead generation at major sleep medicine conferences (SLEEP/AASM, World Sleep Congress), and targeted OEM/white-label licensing. Customers include university hospitals in Korea and the U.S. (Soonchunhyang Bucheon, Seoul Asan, Nevada, Seattle, Miami), pharmaceutical partners for clinical trial collaboration, luxury hotel groups, and corporate wellness programs.

HoneyNaps is pre-IPO, venture-backed, and pursuing a KOSDAQ listing with Korea Investment & Securities as lead underwriter, with a goal of becoming South Korea's first publicly listed sleep tech company. Total disclosed funding is approximately $16.2 million across a 2019 seed (~$700K from TS Investment), a 2021 Series A (~$3.9M), and a February/May 2024 Series B (~$11.6M / 15 billion KRW led by iM Investment Partners, KDB Industrial Bank, QUAD Investment Management, and Albatross Investment). Headcount is in the 11–50 range, and the company holds FDA 510(k), ISO 13485, ISO/IEC 27001, HIPAA, and FCC certifications.

Short descriptiontext

HoneyNaps develops FDA-cleared AI software (SOMNUM) that automates polysomnography analysis for hospitals, sleep centers, pharmaceutical clinical trials, and consumer wellness applications across Korea, the U.S., and other international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI sleep diagnostics, polysomnography analysis software, digital therapeutics insomnia, bio-signal monitoring platform, clinical trial PSG services
Industry5 codes
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
AI Sleep Diagnostics Software
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1AI Software Licensing
TypeSubscription Recurring
Description

HoneyNaps licenses its FDA-cleared SOMNUM AI software to hospitals, sleep centers, and healthcare institutions for automated PSG analysis. Revenue is generated through software deployment contracts with healthcare providers.

prnewswire.com
2Hardware and Device Sales
TypeHardware Sales
Description

Sale of SOMNUM Scanning non-contact sleep monitoring devices and sensors for home use and clinical settings. FCC certified for the U.S. market.

honeynaps.com
3Clinical Trial Services
TypeProfessional Services
Description

HoneyNaps provides AI-based re-scoring services to pharmaceutical and medical device companies conducting clinical trials, significantly reducing trial timelines and costs by automating PSG data analysis.

prnewswire.com
4Technology Licensing
TypeLicensing Royalties
Description

The company receives licensing inquiries from over 60 tier-1 medical device companies and is expanding licensing agreements globally. Pursuing partnerships with pharmaceutical companies for drug development support.

honeynaps.com
5Hospitality Sleep Solutions
TypeSubscription Recurring
Description

Partnerships with hotels (Novotel, InterContinental, Imperial Palace) providing sleep analysis packages and wellness solutions for hotel guests.

honeynaps.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1SOMNUM
Description

FDA-cleared AI sleep disorder diagnosis software that analyzes multi-channel/time-series biosignal data from polysomnography in real time, reducing analysis time from 3-4 hours to approximately 5 minutes. Based on eXplainable Medical AI (XAI) technology.

honeynaps.com
+5 more records
Core offering1 text field

HoneyNaps develops and sells the SOMNUM family of FDA 510(k)-cleared AI sleep disorder diagnosis software that performs real-time automated analysis of multi-channel polysomnography biosignals (EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, snoring), reducing manual scoring from 3-4 hours to approximately 5 minutes. The platform is licensed to hospitals, sleep centers, and pharmaceutical companies for clinical use and clinical trial re-scoring, and is complemented by non-contact SOMNUM Scanning hardware, cloud-based SOMNUM Cloud, and SOMNUM Medella digital therapeutics for insomnia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Analysis time reduced from 3-4 hours to approximately 5 minutes per PSG study
+5 more records
Product overview1 text field

HoneyNaps offers a comprehensive AI-powered sleep healthcare platform centered on SOMNUM technology. The core SOMNUM product is an FDA-cleared AI sleep disorder diagnosis algorithm that analyzes multi-channel biosignals in real-time. The platform includes specialized modules: SOMNUM Scanning (non-contact home sleep monitoring), SOMNUM Cloud (cloud-based PSG analysis), SOMNUM PAX (central monitoring system), and SOMNUM Medella (insomnia digital therapeutic). Additional offerings include HoneyCube bio-signal monitoring platform and newborn sleep monitoring solutions. The company also provides AI-based clinical trial services for pharmaceutical and medical device companies. SOMNUM integrates international medical standards including HL7 and DICOM interfaces.

Product and service8 records
1SOMNUM AI Sleep Diagnosis Software
CategoryAI Sleep Diagnostics Software
Description

FDA 510(k)-cleared deep learning AI software that performs real-time automated analysis of multi-channel polysomnography biosignals (EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, snoring) to assist diagnosis of sleep disorders including sleep staging, respiratory events, arousal events, and leg movements. Designed for hospitals, sleep centers, and pharmaceutical clinical trial use.

2SOMNUM Scanning
CategoryNon-Contact Sleep Monitoring Device
Description

FCC-certified non-contact sleep analysis and coaching hardware that uses radar/sensor technology to collect sleep data at home without electrode attachment. Validated through clinical trials with over 2,000 participants and targeted at home sleep testing.

3SOMNUM Cloud
CategoryCloud-Based PSG Analytics
Description

Cloud-based AI platform that enables users to upload EDF files from PSG systems directly to the cloud for automated AI analysis without requiring local software installation. HIPAA compliance assessment completed for U.S. deployment.

4SOMNUM PAX
CategoryIntegrated Central Monitoring System
Description

All-in-one integrated central monitoring system that combines SOMNUM PSG AI diagnostic software with sleep monitoring capabilities for hospital and clinical environments.

5SOMNUM Medella
CategoryInsomnia Digital Therapeutic
Description

Second-generation digital therapeutic device for insomnia based on digital Sleep Improvement Behavior Therapy for Insomnia (dSIBT-I), combining objective patient sleep analysis from non-contact sensors with AI-personalized cognitive behavioral therapy modules.

6SOMNUM Pro
CategoryClinical AI Sleep Diagnostics
Description

Professional-grade AI sleep diagnostic solution designed for clinical settings and hospital sleep centers, distributed under signed international contracts at World Sleep 2025.

7HoneyCube
CategoryBio-Signal Management Platform
Description

Intelligent bio-signal monitoring platform that collects and analyzes body temperature, heart rate, breathing, and movement during sleep to detect abnormal symptoms early. Supports international standards including HL7, DICOM, and ISO interfaces for hospital, hotel, and individual customer deployments.

8AI Clinical Trial PSG Re-Scoring Service
CategoryClinical Trial AI Services
Description

Service offering for pharmaceutical and medical device companies using SOMNUM AI to re-score PSG data from clinical trials, reducing trial timelines and costs while improving scoring consistency across sites.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Major German Automaker
Strategic tierExploratoryTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Preliminary technical discussions with major German car manufacturer for integration of AI sleep analysis into automotive healthcare solutions. Focus on advanced sensing for driver and passenger monitoring. Presented 'Healthy Sleep in Cars' concept.

honeynaps.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Research collaboration with Professor Ji Ho Choi's team for AI sleep biosignal interpretation system development. SOMNUM developed in partnership with hospital sleep medicine specialists. Professor Choi holds certifications from AASM, ESRS, and WSS.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

MOU signed for development of digital therapeutic solutions for insomnia. Collaboration based on mutual trust to drive digital therapeutics development and establish business model integrated with pharmaceutical industry.

4Seoul Asan Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

Clinical trial partnership with Professor Seokhoon Jeong's team for second-generation insomnia digital therapeutic device (dSIBT-I). Randomized prospective double-blind trial evaluated effectiveness and safety for insomnia treatment.

honeynaps.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Collaborative partnership for executive education program with GS Group, including facility visits and discussions on U.S. bio/medical research trends and dementia/cardiovascular disease research based on sleep data.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Integrated sleep technology into GS Group executive education program for corporate well-being. Conducted sleep analysis for executives and explored sleep market trends and data review.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-01
Description

Business agreement to collaborate on sleep health management AI business platform. Combined HoneyNaps' sleep bio-signal monitoring with KT GiGA Genie solution for personalized healthcare services. Also promoted technology development cooperation using HoneyNaps' X.AI core technology with KT's AI/BigData business endeavors.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-11-01
Description

Joint development of 'sleep diagnosis' cloud platform using big data. Megazone Cloud provides cloud infrastructure expertise while HoneyNaps contributes AI technology and clinical database assets. Platform enables transfer of sleep bio-signal data to hospitals, hotels, and individual customers.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Consumer wearable with sleep tracking and increasingly clinical-grade health insights through partnerships. Adjacent competitor for consumer sleep monitoring and predictive health analytics based on biosignal data.

TypeDirect peer
Description

AI-powered sleep scoring and analysis platform, the only other U.S.-headquartered company with FDA clearance for AI sleep scoring (alongside Cerebra Medical and HoneyNaps). Directly competes with HoneyNaps in automated PSG analysis for hospitals and clinical trials.

TypeBroad incumbent
Description

Global leader in sleep apnea therapy and connected health, with Nox Medical acquisition (2023) expanding into PSG diagnostics. Competes broadly across the sleep healthcare value chain including diagnostics, therapy, and software.

TypeEmerging player
Description

Consumer-grade sleep monitoring headband with AI-driven sleep staging, comparable in technology approach (EEG-based biosignal analysis with deep learning) to HoneyNaps' PSG AI platform, though targeting consumer rather than clinical market.

TypeDirect peer
Description

Australian-listed company manufacturing PSG hardware and analysis software (ProFusion, ProfSleep). Comparable as a vertically integrated sleep diagnostics provider with hospital customers globally.

TypeEmerging player
Description

Digital therapeutic for insomnia (Sleepio) using CBT-I, comparable to HoneyNaps' SOMNUM Medella DTx. Both target the same insomnia treatment market with software-based delivery of CBT-I.

TypeDirect peer
Description

Icelandic PSG hardware and software company offering Nox A1 PSG systems and clinical software. Comparable as an integrated sleep diagnostics provider competing in the same hospital sleep center procurement decisions.

TypeBroad incumbent
Description

Major incumbent in sleep diagnostics and therapy with Alice PSG systems and Sleepware G3 software. Competes as a broader portfolio vendor with significantly larger sales coverage, but HoneyNaps' AI-first approach targets the same sleep center budgets.

TypeEmerging player
Description

U.S.-based sleep diagnostics company providing home sleep testing devices and cloud-based scoring services. Comparable in serving sleep centers and clinical research with PSG/HST solutions.

TypeDirect peer
Description

Canadian AI sleep diagnostic company that, along with EnsoData and HoneyNaps, is one of only three companies globally with FDA clearance for AI sleep scoring. Directly comparable in technology, regulatory positioning, and clinical use case.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HoneyNaps

AI Sleep Diagnostics Softwarehoneynaps.com

HoneyNaps develops FDA-cleared AI software (SOMNUM) that automates polysomnography analysis for hospitals, sleep centers, pharmaceutical clinical trials, and consumer wellness applications across Korea, the U.S., and other international markets.

What HoneyNaps does

HoneyNaps Co., Ltd. is a South Korea-based sleep health technology company founded in 2015 that develops AI-powered software and biosignal monitoring systems for sleep disorder diagnosis, patient management, and digital therapeutics. Its core platform, SOMNUM, is an FDA 510(k)-cleared deep learning algorithm with an eXplainable Medical AI (XAI) framework that performs real-time automated analysis of multi-channel polysomnography (PSG) biosignals — EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, and snoring — reducing expert scoring time from 3–4 hours to approximately 5 minutes per study. The portfolio is organized around the SOMNUM brand and includes SOMNUM Pro (clinical-grade AI sleep diagnostics), SOMNUM Cloud (cloud-delivered EDF file analysis launched August 2025), SOMNUM Scanning (FCC-certified non-contact radar-based home sleep monitoring), SOMNUM PAX (integrated central monitoring system), and SOMNUM Medella (a digital therapeutic for insomnia built on digital CBT-I), supported by the broader HoneyCube bio-signal management platform.

The company generates revenue through five complementary streams: enterprise AI software licensing to hospitals and sleep centers on a recurring basis, hardware sales of SOMNUM Scanning sensors, professional services for AI-based re-scoring of PSG data in pharmaceutical and medical device clinical trials, technology licensing to over 60 tier-1 medical device companies globally, and consumer-facing hospitality and corporate wellness packages (e.g., partnerships with InterContinental, Novotel, and GS Group). Go-to-market is hybrid: direct enterprise field sales through its Seoul headquarters and Boston/Cambridge U.S. subsidiary (HoneyNaps USA Inc.), a developing international distributor network, event-driven lead generation at major sleep medicine conferences (SLEEP/AASM, World Sleep Congress), and targeted OEM/white-label licensing. Customers include university hospitals in Korea and the U.S. (Soonchunhyang Bucheon, Seoul Asan, Nevada, Seattle, Miami), pharmaceutical partners for clinical trial collaboration, luxury hotel groups, and corporate wellness programs.

HoneyNaps is pre-IPO, venture-backed, and pursuing a KOSDAQ listing with Korea Investment & Securities as lead underwriter, with a goal of becoming South Korea's first publicly listed sleep tech company. Total disclosed funding is approximately $16.2 million across a 2019 seed (~$700K from TS Investment), a 2021 Series A (~$3.9M), and a February/May 2024 Series B (~$11.6M / 15 billion KRW led by iM Investment Partners, KDB Industrial Bank, QUAD Investment Management, and Albatross Investment). Headcount is in the 11–50 range, and the company holds FDA 510(k), ISO 13485, ISO/IEC 27001, HIPAA, and FCC certifications.

HoneyNaps firmographics

Firmographics
Name
HoneyNaps
Legal name
HoneyNaps Co., Ltd.
Website
https://honeynaps.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
HoneyNaps develops FDA-cleared AI software (SOMNUM) that automates polysomnography analysis for hospitals, sleep centers, pharmaceutical clinical trials, and consumer wellness applications across Korea, the U.S., and other international markets.
Ownership category
akta.pro rank

HoneyNaps industry classification

Industry
Product category
AI Sleep Diagnostics Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical and Diagnostic Laboratories (6215)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • AI sleep diagnostics
  • Polysomnography analysis software
  • Digital therapeutics insomnia
  • Bio-signal monitoring platform
  • Clinical trial PSG services

Where HoneyNaps is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

HoneyNaps business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI Software Licensing: HoneyNaps licenses its FDA-cleared SOMNUM AI software to hospitals, sleep centers, and healthcare institutions for automated PSG analysis. Revenue is generated through software deployment contracts with healthcare providers.
  2. Hardware and Device Sales: Sale of SOMNUM Scanning non-contact sleep monitoring devices and sensors for home use and clinical settings. FCC certified for the U.S. market.
  3. Clinical Trial Services: HoneyNaps provides AI-based re-scoring services to pharmaceutical and medical device companies conducting clinical trials, significantly reducing trial timelines and costs by automating PSG data analysis.
  4. Technology Licensing: The company receives licensing inquiries from over 60 tier-1 medical device companies and is expanding licensing agreements globally. Pursuing partnerships with pharmaceutical companies for drug development support.
  5. Hospitality Sleep Solutions: Partnerships with hotels (Novotel, InterContinental, Imperial Palace) providing sleep analysis packages and wellness solutions for hotel guests.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

HoneyNaps product offering

Product offering

Core offering

HoneyNaps develops and sells the SOMNUM family of FDA 510(k)-cleared AI sleep disorder diagnosis software that performs real-time automated analysis of multi-channel polysomnography biosignals (EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, snoring), reducing manual scoring from 3-4 hours to approximately 5 minutes. The platform is licensed to hospitals, sleep centers, and pharmaceutical companies for clinical use and clinical trial re-scoring, and is complemented by non-contact SOMNUM Scanning hardware, cloud-based SOMNUM Cloud, and SOMNUM Medella digital therapeutics for insomnia.

Product overview

HoneyNaps offers a comprehensive AI-powered sleep healthcare platform centered on SOMNUM technology. The core SOMNUM product is an FDA-cleared AI sleep disorder diagnosis algorithm that analyzes multi-channel biosignals in real-time. The platform includes specialized modules: SOMNUM Scanning (non-contact home sleep monitoring), SOMNUM Cloud (cloud-based PSG analysis), SOMNUM PAX (central monitoring system), and SOMNUM Medella (insomnia digital therapeutic). Additional offerings include HoneyCube bio-signal monitoring platform and newborn sleep monitoring solutions. The company also provides AI-based clinical trial services for pharmaceutical and medical device companies. SOMNUM integrates international medical standards including HL7 and DICOM interfaces.

Differentiator

Problem solved

Functional benefit

Brands

  • SOMNUM: FDA-cleared AI sleep disorder diagnosis software that analyzes multi-channel/time-series biosignal data from polysomnography in real time, reducing analysis time from 3-4 hours to approximately 5 minutes. Based on eXplainable Medical AI (XAI) technology.
  • SOMNUM Cloud
  • SOMNUM Scanning
  • SOMNUM PAX
  • SOMNUM Medella
  • HoneyCube

Products and services

  • SOMNUM AI Sleep Diagnosis Software FDA 510(k)-cleared deep learning AI software that performs real-time automated analysis of multi-channel polysomnography biosignals (EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, snoring) to assist diagnosis of sleep disorders including sleep staging, respiratory events, arousal events, and leg movements. Designed for hospitals, sleep centers, and pharmaceutical clinical trial use.
  • SOMNUM Scanning FCC-certified non-contact sleep analysis and coaching hardware that uses radar/sensor technology to collect sleep data at home without electrode attachment. Validated through clinical trials with over 2,000 participants and targeted at home sleep testing.
  • SOMNUM Cloud Cloud-based AI platform that enables users to upload EDF files from PSG systems directly to the cloud for automated AI analysis without requiring local software installation. HIPAA compliance assessment completed for U.S. deployment.
  • SOMNUM PAX All-in-one integrated central monitoring system that combines SOMNUM PSG AI diagnostic software with sleep monitoring capabilities for hospital and clinical environments.
  • SOMNUM Medella Second-generation digital therapeutic device for insomnia based on digital Sleep Improvement Behavior Therapy for Insomnia (dSIBT-I), combining objective patient sleep analysis from non-contact sensors with AI-personalized cognitive behavioral therapy modules.
  • SOMNUM Pro Professional-grade AI sleep diagnostic solution designed for clinical settings and hospital sleep centers, distributed under signed international contracts at World Sleep 2025.
  • HoneyCube Intelligent bio-signal monitoring platform that collects and analyzes body temperature, heart rate, breathing, and movement during sleep to detect abnormal symptoms early. Supports international standards including HL7, DICOM, and ISO interfaces for hospital, hotel, and individual customer deployments.
  • AI Clinical Trial PSG Re-Scoring Service Service offering for pharmaceutical and medical device companies using SOMNUM AI to re-score PSG data from clinical trials, reducing trial timelines and costs while improving scoring consistency across sites.

Quantifiable outcome

  • Analysis time reduced from 3-4 hours to approximately 5 minutes per PSG study
  • +5 more outcomes

Companies that use HoneyNaps

Customer profile

Named customers9 records

Segments6 records

Ideal customer profiles4 records

HoneyNaps technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

HoneyNaps partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered exploratory, core and minor.

  • Major German AutomakerexploratoryStrategic or Co-development Partner · 1 May 2024Preliminary technical discussions with major German car manufacturer for integration of AI sleep analysis into automotive healthcare solutions. Focus on advanced sensing for driver and passenger monitoring. Presented 'Healthy Sleep in Cars' concept.
  • Soonchunhyang University Bucheon HospitalcoreStrategic or Co-development Partner · 1 August 2023Research collaboration with Professor Ji Ho Choi's team for AI sleep biosignal interpretation system development. SOMNUM developed in partnership with hospital sleep medicine specialists. Professor Choi holds certifications from AASM, ESRS, and WSS.
  • Whan In PharmcoreStrategic or Co-development Partner · 1 May 2023MOU signed for development of digital therapeutic solutions for insomnia. Collaboration based on mutual trust to drive digital therapeutics development and establish business model integrated with pharmaceutical industry.
  • Seoul Asan HospitalcoreStrategic or Co-development Partner · 1 May 2023Clinical trial partnership with Professor Seokhoon Jeong's team for second-generation insomnia digital therapeutic device (dSIBT-I). Randomized prospective double-blind trial evaluated effectiveness and safety for insomnia treatment.
  • University of Washington / Harborview Medical CenterminorStrategic or Co-development Partner · 1 January 2023Collaborative partnership for executive education program with GS Group, including facility visits and discussions on U.S. bio/medical research trends and dementia/cardiovascular disease research based on sleep data.
  • GS GroupminorStrategic or Co-development Partner · 1 January 2023Integrated sleep technology into GS Group executive education program for corporate well-being. Conducted sleep analysis for executives and explored sleep market trends and data review.
  • KT CorporationcoreStrategic or Co-development Partner · 1 December 2020Business agreement to collaborate on sleep health management AI business platform. Combined HoneyNaps' sleep bio-signal monitoring with KT GiGA Genie solution for personalized healthcare services. Also promoted technology development cooperation using HoneyNaps' X.AI core technology with KT's AI/BigData business endeavors.
  • Megazone CloudcoreTechnology or Integration · 1 November 2020Joint development of 'sleep diagnosis' cloud platform using big data. Megazone Cloud provides cloud infrastructure expertise while HoneyNaps contributes AI technology and clinical database assets. Platform enables transfer of sleep bio-signal data to hospitals, hotels, and individual customers.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

HoneyNaps competitors and assessment

Company assessment

Emerging players

  • Oura: Consumer wearable with sleep tracking and increasingly clinical-grade health insights through partnerships. Adjacent competitor for consumer sleep monitoring and predictive health analytics based on biosignal data.
  • Dreem: Consumer-grade sleep monitoring headband with AI-driven sleep staging, comparable in technology approach (EEG-based biosignal analysis with deep learning) to HoneyNaps' PSG AI platform, though targeting consumer rather than clinical market.
  • Big Health (Sleepio): Digital therapeutic for insomnia (Sleepio) using CBT-I, comparable to HoneyNaps' SOMNUM Medella DTx. Both target the same insomnia treatment market with software-based delivery of CBT-I.
  • CleveMed: U.S.-based sleep diagnostics company providing home sleep testing devices and cloud-based scoring services. Comparable in serving sleep centers and clinical research with PSG/HST solutions.

Direct peers

  • EnsoData: AI-powered sleep scoring and analysis platform, the only other U.S.-headquartered company with FDA clearance for AI sleep scoring (alongside Cerebra Medical and HoneyNaps). Directly competes with HoneyNaps in automated PSG analysis for hospitals and clinical trials.
  • Compumedics: Australian-listed company manufacturing PSG hardware and analysis software (ProFusion, ProfSleep). Comparable as a vertically integrated sleep diagnostics provider with hospital customers globally.
  • Nox Medical: Icelandic PSG hardware and software company offering Nox A1 PSG systems and clinical software. Comparable as an integrated sleep diagnostics provider competing in the same hospital sleep center procurement decisions.
  • Cerebra Medical: Canadian AI sleep diagnostic company that, along with EnsoData and HoneyNaps, is one of only three companies globally with FDA clearance for AI sleep scoring. Directly comparable in technology, regulatory positioning, and clinical use case.

Broad incumbents

  • ResMed: Global leader in sleep apnea therapy and connected health, with Nox Medical acquisition (2023) expanding into PSG diagnostics. Competes broadly across the sleep healthcare value chain including diagnostics, therapy, and software.
  • Philips Respironics: Major incumbent in sleep diagnostics and therapy with Alice PSG systems and Sleepware G3 software. Competes as a broader portfolio vendor with significantly larger sales coverage, but HoneyNaps' AI-first approach targets the same sleep center budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

HoneyNaps compliance and trust

Trust signal

Compliance5 records

HoneyNaps financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HoneyNaps leadership team

Management profile

Number of profiles

Profiles4 records

HoneyNaps subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

HoneyNaps funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HoneyNaps M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HoneyNaps

What does HoneyNaps do?

HoneyNaps develops and sells the SOMNUM family of FDA 510(k)-cleared AI sleep disorder diagnosis software that performs real-time automated analysis of multi-channel polysomnography biosignals (EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, snoring), reducing manual scoring from 3-4 hours to approximately 5 minutes. The platform is licensed to hospitals, sleep centers, and pharmaceutical companies for clinical use and clinical trial re-scoring, and is complemented by non-contact SOMNUM Scanning hardware, cloud-based SOMNUM Cloud, and SOMNUM Medella digital therapeutics for insomnia.

Is HoneyNaps a public or private company?

HoneyNaps is a private company. It is classified as venture growth investor backed and is currently operating.

When was HoneyNaps founded?

HoneyNaps was founded in 2015. It employs 11 to 50 people.

Where is HoneyNaps based?

HoneyNaps is headquartered in Seoul, South Korea, in the Asia region.

How does HoneyNaps make money?

Five revenue lines are on record. AI Software Licensing is the primary driver. The others are hardware and Device Sales, clinical Trial Services, technology Licensing and hospitality Sleep Solutions.

Who are HoneyNaps's main competitors?

Emerging players on record are Oura, Dreem, Big Health (Sleepio) and CleveMed. Direct peers are EnsoData, Compumedics, Nox Medical and Cerebra Medical. Broad incumbents are ResMed and Philips Respironics.

Does HoneyNaps have an API?

No public API is recorded for HoneyNaps.

What industry is HoneyNaps in?

HoneyNaps's product category is AI Sleep Diagnostics Software. Its primary akta.pro industry code is HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy), with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACHoneyNaps Selected for 2026 Eurostars International R&D ProjectHoneyNaps, a South Korean sleep medicine AI company, was selected for a 2026 Eurostars international R&D project supported by Korean and EU funding. The consortium will develop a non-invasive platform to monitor intracranial pressure and sleep status, targeting Technology Readiness Level 6. The project aims to prepare for submission under the EU Medical Device Regulation.PR NewswireHoneyNaps Selected for 2026 Eurostars International R&D ProjectHoneyNaps was selected for a 2026 Eurostars R&D project with Yonsei, Dankook, Uppsala, and Xantage to develop a non-invasive neurological monitoring platform. The project combines electromagnetic sensing, AI, and wireless polysomnography to estimate intracranial pressure and sleep stages, aiming for TRL 6 and EU MDR preparation.PR Newswire APACAdvances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial EfficiencyHoneyNaps, an AI-based sleep health company, completed registration as a clinical research organization with Korea's KoNECT. It expands its clinical analysis services beyond sleep scoring, targeting pharmaceutical, wellness, and medical device sectors. The company aims to diversify revenue and support future digital biomarker development.PR NewswireAdvances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial EfficiencyHoneyNaps, an AI-based sleep health company, has registered as a clinical research organization with KoNECT and is expanding its clinical analysis services. The company combines AI-powered sleep analysis with experience supporting trials involving over 10,000 participants. It aims to diversify revenue by broadening applications beyond sleep scoring.AInvestFour Patches Replace 24 Wires. The Money Is in Who Gets to Leave the LabHoneyNaps, a South Korean sleep-tech startup, replaced 24 wired sensors with four skin patches for home-based sleep diagnostics, using AI scoring via SOMNUM software. The system cuts manual scoring time from hours to minutes, but HoneyNaps remains private with no public listing, so investors must track downstream therapy providers like CPAP and implant companies.PR Newswire APACHoneyNaps Develops Next-Generation Wireless PSG system Using Four Skin PatchesHoneyNaps developed a wireless polysomnography system using four skin patches to replace over 24 wired sensors. The system captures EEG, EOG, ECG, EMG, respiratory airflow, and SpO2, with AI-powered analysis via SOMNUM software. It aims to enable home sleep testing and remote monitoring.PR NewswireHoneyNaps Develops Next-Generation Wireless PSG system Using Four Skin PatchesHoneyNaps developed a wireless polysomnography system using four skin patches to replace over 24 wired sensors. The system captures EEG, EOG, ECG, EMG, respiratory airflow, SpO2, and body position, with AI-powered analysis via SOMNUM software. It aims to enable home sleep testing and remote monitoring.MorningstarHoneyNaps Develops Next-Generation Wireless PSG system Using Four Skin PatchesHoneyNaps developed a wireless polysomnography system using four skin patches to replace over 24 wired sensors. The system captures EEG, EOG, ECG, EMG, respiratory airflow, SpO2, body position, and activity, with AI-powered analysis via SOMNUM software. It aims to enable home sleep testing and remote monitoring.YahooPhilips Korea and HoneyNaps Sign Strategic MOU to Advance Sleep and Cardiovascular HealthPhilips Korea and HoneyNaps signed a memorandum of understanding on August 19, 2026, to explore healthcare opportunities at the intersection of sleep disorders and cardiovascular disease. The companies will jointly identify medical and healthcare business opportunities, examine the link between sleep and cardiovascular health, and explore expansion into cardiology. The article was cut off before disclosing financial terms or a timeline.PR NewswirePhilips Korea and HoneyNaps Sign Strategic MOU to Advance Sleep and Cardiovascular HealthPhilips Korea and AI-powered sleep medicine company HoneyNaps signed a memorandum of understanding on August 19, 2026, to explore healthcare opportunities at the intersection of sleep disorders and cardiovascular disease. The partnership will examine how sleep data integrates with cardiovascular risk factors, expand into cardiology, and pursue academic initiatives. No financial terms were disclosed.